Mimedx (MDXG) Total Non-Current Liabilities (2010 - 2026)
Mimedx recorded quarterly Total Non-Current Liabilities of $60.6 million in Q1 2026, down 24.88% quarter-over-quarter from $80.7 million in Q4 2025, and up 0.82% year-over-year from $60.2 million in Q1 2025.
Mimedx's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $60.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 0.82% year-over-year to $60.6 million; the TTM figure through Mar 2026 stood at $60.6 million (up 0.82% YoY), while the FY2025 annual figure was $80.7 million, up 27.29% from the prior year.
- Total Non-Current Liabilities came in at $60.6 million for Q1 2026 at Mimedx, down from $80.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $94.3 million in Q3 2022 to a low of $58.3 million in Q2 2024.
- A 5-year average of $77.2 million and a median of $80.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 37.55% in 2024 and advanced 27.29% in 2025, its largest moves.
- Mimedx's Total Non-Current Liabilities stood at $92.2 million in 2022, then increased by 2.12% to $94.1 million in 2023, then slumped by 32.6% to $63.4 million in 2024, then gained by 27.29% to $80.7 million in 2025, then fell by 24.88% to $60.6 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $60.6 million, $80.7 million, and $74.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 60.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.64 Mn |
| Dec 31, 2025 | 80.73 Mn |
| Sep 30, 2025 | 74.52 Mn |
| Jun 30, 2025 | 67.50 Mn |
| Mar 31, 2025 | 60.15 Mn |
| Dec 31, 2024 | 63.43 Mn |
| Sep 30, 2024 | 59.96 Mn |
| Jun 30, 2024 | 58.26 Mn |
| Mar 31, 2024 | 60.67 Mn |
| Dec 31, 2023 | 94.11 Mn |
| Sep 30, 2023 | 92.59 Mn |
| Jun 30, 2023 | 93.30 Mn |
| Mar 31, 2023 | 89.58 Mn |
| Dec 31, 2022 | 92.15 Mn |
| Sep 30, 2022 | 94.33 Mn |
| Jun 30, 2022 | 85.49 Mn |
| Mar 31, 2022 | 84.83 Mn |
| Dec 31, 2021 | 90.48 Mn |
| Sep 30, 2021 | 89.76 Mn |
| Jun 30, 2021 | 98.48 Mn |
| Mar 31, 2021 | 103.21 Mn |
| Dec 31, 2020 | 106.86 Mn |
| Sep 30, 2020 | 104.92 Mn |
| Jun 30, 2020 | 125.14 Mn |
| Mar 31, 2020 | 125.34 Mn |
| Dec 31, 2019 | 129.23 Mn |
| Sep 30, 2019 | 135.54 Mn |
| Jun 30, 2019 | 141.17 Mn |
| Mar 31, 2019 | 64.35 Mn |
| Dec 31, 2018 | 71.55 Mn |
| Dec 31, 2017 | 45.81 Mn |
| Sep 30, 2017 | 36.24 Mn |
| Jun 30, 2017 | 51.51 Mn |
| Mar 31, 2017 | 58.37 Mn |
| Dec 31, 2016 | 68.33 Mn |
| Sep 30, 2016 | 57.56 Mn |
| Jun 30, 2016 | 39.47 Mn |
| Mar 31, 2016 | 29.74 Mn |
| Dec 31, 2015 | 27.93 Mn |
| Sep 30, 2015 | 24.35 Mn |
| Jun 30, 2015 | 19.46 Mn |
| Mar 31, 2015 | 18.46 Mn |
| Dec 31, 2014 | 18.40 Mn |
| Sep 30, 2014 | 14.45 Mn |
| Jun 30, 2014 | 9.91 Mn |
| Mar 31, 2014 | 9.59 Mn |
| Dec 31, 2013 | 9.61 Mn |
| Sep 30, 2013 | 8.33 Mn |
| Jun 30, 2013 | 6.14 Mn |
| Mar 31, 2013 | 5.97 Mn |
| Dec 31, 2012 | 14.82 Mn |
| Sep 30, 2012 | 14.04 Mn |
| Jun 30, 2012 | 11.48 Mn |
| Mar 31, 2012 | 14.04 Mn |
| Dec 31, 2011 | 14.89 Mn |
| Sep 30, 2011 | 11.65 Mn |
| Jun 30, 2011 | 11.33 Mn |
| Dec 31, 2010 | 1.25 Mn |